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Abstract
New psychoactive substances (NPS) have been introduced into themarket in recent years, with new analytes reported every year. The
use of these substances in women can occur at any stage of life, even in the childbearing age. Drug use during pregnancy presents
significant risks for the mother and the fetus, so it is important to have tools that allow to detect prenatal exposure to these substances
of abuse. Therefore, an analytical method for the determination of 137NPS and other drugs of abuse inmeconium byUHPLC-QTOF
was developed and validated for semi-quantitative purpose. Linearity range, limit of detection (LOD), precision, matrix effect,
selectivity, and specificity were evaluated. For all analytes, the calibration curves were studied in the ranges between 2, 10, or
50 ng/g and 750 or 1000 ng/g, (depending on the analyte) and the LOD ranged between 0.04 and 2.4 ng/g. The method was applied
to 30 meconium specimens from cases in which fentanyl had been administered as epidural anesthesia at the time of delivery or cases
in which the maternal hair was positive to other drug of abuse. Four meconium samples tested positive for fentanyl (range concen-
tration = 440–750 ng/g) and two samples tested positive to acetylfentanyl (range concentration = 190–1400 ng/g).
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Introduction
New psychoactive substances (NPS) are new chemicals de-
signed tomimic the effects of classic drugs (cocaine, cannabis,
heroine, etc.). UNODC was the first to use the term NPS to
refer to “substances of abuse, either in a pure form or a prep-
aration, that are not controlled by the 1961 Single Convention
on Narcotic Drugs or the 1971 Convention on Psychotropic
Substances, but which may pose a public health threat” [1].
Different NPS are reported every year and their presence has
already been detected in more than 100 countries. Due to their
unregulated status, these drugs were initially sold on the
Internet as “legal highs” or “bath salts,” so efforts have been
made to speed up the legislation on their production and dis-
tribution [2]. The main substance groups of NPS present in the
market in 2019were stimulants (36%), synthetic cannabinoids
(31%), classic hallucinogens (15%), and opioids (8%) [1].
To collect information about the prevalence of use, several
countries have recently included NPS in their national drug sur-
veys. In 2017, 1% of the Spanish adult population consumed
NPS [3] compared to the 2–11% who consumed classical drugs
such as cannabis or cocaine [4]. The prevalence of NPS use
decreases to 0.7% in the group of women of childbearing age
(15–44 years old) [4]. Opioids are the NPS group of greatest
concern nowadays. In the USA, the opioid epidemic is caused
by the increasing prevalence of the use of synthetic opioids and
fentanyl analogs. Although this is not yet the situation in Europe,
several concerns have been raised [5, 6]. Moreover, in Spain
between 8.3 and 18.3% of women of childbearing age admitted
using analgesic opioids at some point in their lives [4].
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Pregnant women are a very vulnerable group to the harmful
effects of drugs because its use during pregnancy can have
negative effects on both the mother and the fetus. Monitoring
of opioids use during pregnancy is especially important, since
besides their possible illicit use, these drugs are used for pain
management (epidural anesthesia) or to treat drug addiction
[7]. Prenatal exposure to drugs is mostly related to neonatal
abstinence syndrome (NAS), but also to low birth weight and
preterm delivery [8–10]. Therefore, it is important to detect
prenatal exposure to psychoactive substances. Meconium
analysis is considered the gold standard for detection of pre-
natal drug exposure [11, 12]. Meconium is the first stool of
newborn and its composition is very complex, which can
make it difficult to analyze. On the other hand, it is advanta-
geous since its analysis provides information on the direct
fetal exposure and its detection window is very wide, covering
the second and third trimesters of pregnancy [11, 12].
Only three procedures have been published for the identi-
fication of several NPS in meconium [13–15]. So, to our
knowledge, this is the first large multianalyte method for the
identification of NPS in meconium. Besides, previous
methods were developed with LC–MS/MS, which is in turn
limited by the necessity to constantly update the analytical
method with the new NPS emerging every day in the black
market. In this sense, a QTOF technique by data-independent
acquisition with sequential window acquisition of all theoret-
ical fragment-ion mass spectra (SWATH) is more recom-
mended, since it solves the limitations present in conventional
mass spectrometers. This technique consists in a full scan of
every detectable analyte present in the biological matrix by
covering a wide mass range in several cycles. For each cycle,
the instrument focuses on a small mass window of precursors
and acquiresMS/MS data from all precursors detected [16]. In
addition, with this technique, new compounds can be added
without changing the acquisition method, and retrospective
analysis can be performed without the need to re-analyze the
sample, since the SWATH acquisition collects MS and MS/
MS information on each detectable peak. This is a great ad-
vantage as the sample quantity is sometimes scarce.
Thus, the aim of the present work was to develop and
validate an analytical method for the determination of 137
NPS and metabolites in meconium by UHPLC-QTOF. Once
validated, the method was applied to meconium specimens
from cases in which fentanyl had been administered as epidu-
ral anesthesia at the time of delivery.
Materials and methods
Reagents and standards
All chemicals, including methanol, formic acid, dichloro-
methane, 2-propanol, ammonium hydroxide, and
hydrochloric acid, were purchased from Sigma-Aldrich
(Milan, Italy). Ultra-pure water was obtained using a Milli-
Q® UF-Plus apparatus (Millipore, Bedford, MA, USA). All
stock standard solutions were prepared in methanol at 1 mg/
mL and stored at − 20 °C until used. Working solutions were
prepared at the final concentration of 1000 ng/mL by dilution
with methanol. SPE MCX cartridges (3 cm3, 60 mg) were
acquired from Teknokroma (Barcelona, Spain).
Blank meconium specimens used for the preparation of the
calibration curves were collected at the University Hospital of
Vigo (Galicia, Spain) from newborns whose mothers were not
suspicious of drug use during pregnancy. Meconium was col-
lected at the hospital from newborn diapers up to 3 days after
delivery, and stored in polypropylene containers at − 20 °C
until analysis.
Moreover, 30 authentic meconium specimens were ana-
lyzed to prove the method applicability. These specimens
were collected at the University Hospitals of Santiago de
Compostela and Vigo (Galicia, Spain) from January 2012 to
December 2015. Recruitment was done after delivery and
mothers, who accepted to participate in the study and signed
a written informed consent, were not paid for their participa-
tion. Real samples collection was approved by the Galician
Clinical Research Ethics Committee (Xunta de Galicia, Spain;
code number: 2011/203).
Sample preparation
The sample was prepared following a previously published
homogenization and extraction procedure [15]. Briefly, meco-
nium (0.25 ± 0.02 g) was homogenized with 2 mL of metha-
nol and 25 μL of the IStd solution at 1 μg/mL by sonication
for 30 min. After centrifugation, the sample was evaporated to
dryness under nitrogen at 45 °C. Then, the extract was
reconstituted in 2 mL of 2% formic acid in H2O for solid-
phase extraction (SPE). After cartridges conditioning (2 mL
methanol + 2 mL water), the sample was loaded. Then, the
column was subsequently washed with 2 mL of 2% formic
acid in H2O and 2 mL of methanol/water/formic acid
(47.5:47.5:5, v/v/v). After drying under vacuum for 10 min,
analytes were eluted with 2 mL of dichloromethane/2-
propanol/ammonium hydroxide (47.5:47.5:5, v/v/v). The final
eluent of the SPE was evaporated to dryness with nitrogen at
45 °C and then reconstituted with 50 μL of methanol; finally,
5 μL were injected into the UHPLC-QTOF. Before each
evaporation step, 50 μL of 1% HCl in methanol were added
to prevent analyte evaporation.
Instrumentation
UHPLC separation was performed on a Phenomenex Kinetex
C18 column (100 × 2.1 mm, 1.7 μm) at 45 °C on the SCIEX
ExionLC™AC system. Mobile phases consisted of water (A)
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and acetonitrile (B), both with 5 mM of formic acid. The LC
flow rate was 0.5 mL and the mobile phase eluted under the
following linear gradient conditions: (A:B, v/v) isocratic elu-
tion at 95:5 for 0.5 min, from 95:5 to 5:95 in 7.5 min, isocratic
elution at 5:95 for 0.5 min, and final re-equilibration for
2.5 min to the initial condition before each injection. Total
run time was 10 min.
All analyses were performed using a quadrupole time-of-
flight SCIEX X500R QTOF mass spectrometer (Sciex,
Darmstadt, Germany) equipped with a Turbo VTM ion source
operating in electrospray positive-ion mode. MS and MS/MS
data were collected for each sample using SWATH™
Acquisition mode [17]. Data acquisition included a prelimi-
nary TOF-MS high-resolution scan followed by SWATH™
Acquisition using variable window setup (12 windows cover-
ing mass range from 150 to 465m/z at 0.025 resolving power),
resulting in a final cycle time of 0.564 s. Data were acquired
using the SCIEX OS 1.5 Software.
Method validation
Validation was performed according to a protocol published
by Alladio et al. [18, 19]. Three calibration curves with 6
concentration levels were analyzed on 3 different days (3 ×
3 × 6), and with these 54 data points, the main validation pa-
rameters were evaluated: calibration, intra- and inter-day pre-
cision and accuracy, limit of detection (LOD), selectivity,
specificity, and carry-over. The method was only validated
for semi-quantitative purposes.
Calibration
The heteroscedasticity of the data points was evaluated using
an F-test integrated in the R routine. If the system was
heteroscedastic, we selected the weighted model (linear or
quadratic) that generates the smallest variance. Finally, the
calibration model was calculated and the analysis of variance
lack of fit (ANOVA-LoF) test was performed to verify it.
LOD
LODs were estimated using the Hubaux–Vox approach.
When the analyte shows a quadratic trend, the highest levels
of the calibration curve were eliminated until the trend was
linear in order to calculate the LODs.
Precision and accuracy
Precision was evaluated using the coefficient of variation
(%CV). Intra-day precision was evaluated calculating a cali-
bration model for each day of validation, which was used to
back-calculate the three experimental replicates performed the
same day and then the %CV was calculated. While inter-day
precision was computed by back calculating all the nine rep-
licates using the comprehensive calibration curve. Intra- and
inter-day precision were considered validated when the aver-
age of all the calibration levels was below 30%.
Intra-day accuracy was evaluated by a back-calculation of
each data point using the calibration curves that did not in-
clude it. Two calibration curves were used to compute the
calibration model using the R routine, then this model was
used to back-calculate the third calibration curve and with
the average of all the results, the overall bias was calculated,
while inter-day accuracy was calculated in the same way but
using the data point from the calibration curves of the other
2 days. Intra- and inter-day accuracy were considered validat-
ed when the average of the bias in all the calibration levels was
below 20%.
Since the method was validated for semi-quantitative pur-
poses, only inter-day precision was studied.
Matrix effect
Due to the potential variability in matrix composition obtained
from different sources, matrix effect (ME) was investigated
using 5 samples which were previously screened to confirm
the absence of the analytes of interest [20]. ME studies were
performed using the addition technique of the analytes and
internal standards (IStd) to blank samples after their extrac-
tion. In this experiment, two sets of solutions of analytes and
IStd were prepared at low (50 ng/g) and high (1000 ng/g)
concentration levels within the method linear range: in meth-
anol (set A) and in matrix extracts obtained from meconium
samples (set B). The matrix effect (±%) can be explained as
















The presence of endogenous and exogenous interferences was
checked by examining in the chromatogram the presence of
interfering peaks with a signal/noise ratio above three around
the retention time of the analytes. There must be an absence of
interferences to validate the method.
Carry-over
The carry-over was studied by injecting 10 replicates of a
blank sample meconium after the highest point of the calibra-
tion curve. It was considered validated when the signal was
not greater than 20% of the LODs [21].
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Application to real specimens
Thirty paired meconium and maternal hair specimens from
cases in which fentanyl had been administered as epidural
anesthesia at the time of delivery (n = 27) or cases in which
there was suspicion of drug abuse (n = 3) were studied.
Meconium specimens were analyzed with the present
method to proof its applicability. Maternal hair specimens
were analyzed using a previously published LC–MS/MS
method that allows the determination of 35 analytes, including
opioids, cocaine, amphetamines, cannabis, lysergic acid
diethylamide, ketamine, scopolamine, antidepressants, benzo-
diazepines, and zolpidem [22]. Briefly, maternal hair (50 mg)
was collected after delivery from the vertex posterior region,
as close as possible to the scalp, and stored at room tempera-
ture. Maternal hair (8 cm) was divided into 3 segments corre-
sponding with the 3 trimesters of pregnancy and individually
analyzed: from 0 (root) to 2 cm, corresponding to the third
trimester; from 3 to 5 cm, corresponding to the second trimes-
ter; and from 6 to 8 cm, corresponding to de first trimester.
Results and discussion
The purpose of this publication was to develop and validate a
screening method for the determination of NPS in meconium
by UHPLC-QTOF. Other procedures for the detection of NPS
in meconium have been published [13–15], but the number of
target analytes was limited. Moreover, all these methods were
developed in targeted LC-MS/MS, a valid analysis technique
in most cases but with a limited capacity of detecting
multianalyte when new compounds are constantly introduced
into the market.
Meconium was prepared following a previously published
homogenization and extraction procedure for the determina-
tion of 6 synthetic cathinones [15]. Therefore, it was demon-
strated that this procedure could also be applied to the analysis
of more than 100 very different compounds. Screening
methods for the determination of NPS in other biological ma-
trices have been published and, in all of them, the challenge of
monitoring such many substances was observed [22–26]. As
in the present method, all the mentioned analytical methods
carried out an extraction procedure (liquid–liquid or solid-
phase) [23–26] or even two separate extractions [22], paying
special attention to the choice of the extraction solvent in order
to achieve good recovery for all the compounds, which have
varying chemical structures.
Method validation
The total chromatographic run time was achieved in only
10 min and the retention time ranged between 0.7 min
(psylocibin) and 8.03 min (AKB-48 APINACA). The method
was validated for semi-quantitative purposes for all compounds
listed in Tables 1 and 2, including 54 synthetic cannabinoids or
metabolites; 49 synthetic cathinones, stimulants, hallucinogens,
and metabolites; and 34 synthetic opioids and metabolites.
For all analytes, the calibration data points proved to have
heteroscedastic distribution, using 1, 1/x and 1/x2 as a
weighting factor depending on the analyte (Table 1). The cal-
ibration curves were studied in the ranges between 2, 10, or
50 ng/g and 750 or 1000 ng/g, depending on the analyte. The
calibration curves for the following analytes proved quadratic
within the calibration range: 5-F-APINACA, AKB-48
APINACA, AM-1220, JWH-019, JWH-020, JWH-073,
JWH-122, JWH-147, JWH-398, MDMB-CHMICA,
MDMB-CHMINACA,PB-22, 25B-NBOMe, 25C-NBOMe,
25H-NBOMe, 25I-NBOMe, 2-CB, 2-CP, 4-Acetoxy-DMT,
4-MEC, 5-EAPB, 5-methoxy DALT, 5-OH-tryptophan,
butylone, ethylone, ethylphenidate, ethyltryptamine, harmine,
mescaline, methylone, mitragynine, N-ethylpentylone,
pentylone, 3-methylnorfentanyl, 4-ANPP, 4-methyl fentanyl,
acetyl fentanyl, acetyl norfentanyl, acrylfentanyl, alfentanyl,
butyrylfentanyl, butyryl norfentanyl, carfentanyl,
cyc lopropyl fen tanyl , fen tanyl , fu rany l fen tanyl ,
furanylnorfentanyl, methoxyacetyl norfentanyl, norfentanyl,
ocfentanyl, OH-fentanyl, thiofentanyl, remifentanyl,
sufentanyl, tramadol, U47700, valeryl fentanyl carboxy me-
tabolite, and β-phenylfentanyl, while for the rest of the
analytes a linear fitting was more suitable. All the equations
for the final calibration models are also reported in Table 1.
LOD ranged between 0.04 and 2.4 ng/g (Table 1), while
LOD described by other authors [12–14] were much higher
(0.5–10 ng/g). Moreover, Pichini et al. [13] method uses 0.5 g
of meconium, which is twice what was used in this method,
while Nemeškalová et al. [14] and López-Rabuñal et al. [15]
methods use a similar amount of meconium. Using a lower
amount of sample is crucial because it allows additional drug
analysis when the specimen quantity is limited.
Inter-day precision (expressed as percent variation coeffi-
cient, CV%)were found to be between 0.0 and 71.5 (Table 2).
Matrix effect ranged from − 70 to 72% for synthetic cannabi-
noids, − 89 to 71% for synthetic cathinones and hallucino-
gens, and − 88 to 110% for fentanyl analogous and synthetic
opioids. Matrix effect varied from signal suppression to high
signal enhancement due to coeluting endogenous substances,
and significant values were obtained for most compounds
(only matrix effect between − 20 and 20% are considered
negligible). Matrix effect results are shown in Table 3.
No endogenous and/or exogenous interferences with a
signal/noise ratio above 3 were detected around the retention
time of the analytes; therefore, selectivity and specificity were
verified for all analytes. Finally, the absence of any carry-over
effect was checked, since for all analytes, the blank samples
injected after the higher level of calibration curve had no rel-
evant signal.
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Table 1 Calibration model parameters, LOD, and LOQ for all the compounds
Compound LOD (ng/g) Calibration
range (ng/g)
Weight Model Equation Squared correlation
coefficient (r2)
Synthetic cannabinoids
5-Chloro-AB-PINACA 0.3 2–1000 1/x2 Linear 0.1108 x+0.009756 0.9996
5-Chloro-TH-J018 0.25 10–1000 1/x2 Linear 0.03827 x − 0.0003938 0.9819
5-F-AB-PINACA 0.3 2–1000 1/x2 Linear 0.09489 x+0.009723 0.9981
5-F-ADB 0.3 2–1000 1/x2 Linear 0.4424 x+0.05326 0.9945
5-F-APINACA 1 10–750 1/x Quadratic −0.2416 x2+4.825 x+0.3457 0.7398
5-F-APP PICA 0.4 2–750 1/x2 Linear 0.4928 x+0.08252 0.9976
5-F-APP PINACA 0.3 10–1000 1/x2 Linear 0.1738 x − 0.00544 0.9926
5-F-CUMYL PINACA 0.4 2–750 1/x2 Linear 0.6808 x+0.1156 0.9826
5-F NNEI 2′-naphthyl isomer 0.7 2–750 1/x Linear 0.3296 x+0.06084 0.9957
AB-CHMINACA 0.3 2–1000 1/x2 Linear 0.2223 x+0.02269 0.9965
AB-FUBINACA 0.5 2–750 1/x Linear 0.1126 x+0.01023 0.9982
AB-PINACA 0.25 10–1000 1/x2 Linear 0.2159 x+0.005061 0.9989
ADB-FUBINACA 0.4 2–750 1/x Linear 0.1153 x+0.008009 0.9971
ADBICA 0.6 2–750 1/x Linear 0.336 x+0.04333 0.997
ADB-PINACA 0.3 2–1000 1/x2 Linear 0.2111 x+0.02225 0.9987
AKB-48 APINACA 0.3 2–750 1/x Quadratic −0.003394 x2+0.1206 x+0.01288 0.9915
AM-1220 0.1 10–1000 1/x2 Quadratic 0.005469 x2+0.296 x − 0.01568 0.9964
AM-2201 0.6 2–750 1/x Linear 0.1377 x+0.01795 0.9991
AM-2233 0.2 10–1000 1/x2 Linear 1.258 x − 0.06359 0.993
AM-694 0.3 2–1000 1/x2 Linear 0.07424 x+0.007622 0.9981
APP-FUBINACA 0.3 2–750 1/x2 Linear 0.1132 x+0.009388 0.991
CUMYL-PeGACLONE 0.3 2–750 1/x2 Linear 1.543 x+0.1826 0.8529
JWH-007 0.5 2–750 1/x Linear 0.4384 x+0.05555 0.9986
JWH-015 0.4 2–750 1/x Linear 0.4562 x+0.04051 0.9957
JWH-016 0.6 2–1000 1/x Linear 0.6233 x+0.07023 0.9987
JWH-018 0.6 2–1000 1/x Linear 0.6247 x+0.07083 0.9987
JWH-019 0.3 2–750 1/x Quadratic −0.002751 x2+0.1765 x+0.01267 0.9959
JWH-020 0.3 10–1000 1/x Quadratic −0.000976 x2+0.0729 x − 0.001472 0.9934
JWH-073 0.1 2–750 1/x2 Quadratic −0.02009 x2+0.6237 x+0.001378 0.899
JWH-081 0.5 2–750 1/x Linear 0.3621 x+0.09221 0.9973
JWH-098 0.1 2–500 1/x2 Linear 0.2778 x+0.01005 0.9837
JWH-122 0.3 2–750 1/x Quadratic −0.002569 x2+0.1695 x+0.01332 0.9979
JWH-147 0.04 2–500 1/x2 Quadratic −0.008044 x2+0.2343 x − 0.0004362 0.9853
JWH-203 0.3 2–750 1/x2 Linear 0.1766 x+0.01617 0.9994
JWH-210 0.3 2–1000 1/x2 Linear 0.109 x+0.01019 0.9964
JWH-250 0.3 2–500 1/x2 Linear 16.36 x+1.573 0.8404
JWH-251 0.3 2–750 1/x2 Linear 0.4398 x+0.05204 0.998
JWH-302 0.3 2–750 1/x2 Linear 0.2207 x+0.02539 0.9985
JWH-307 0.1 2–500 1/x2 Linear 0.2791 x+0.01007 0.9839
JWH-398 0.2 10–1000 1/x2 Quadratic −0.0008424 x2+0.05617 x − 0.0001841 0.9951
MAB-CHMINACA 0.3 2–750 1/x2 Linear 0.2734 x+0.02795 0.997
MAM-2201 0.3 2–500 1/x2 Linear 0.4105 x+0.04215 0.9957
MDMB-CHMICA 1.1 50–1000 1/x2 Quadratic −0.0002132 x2+0.00765 x+0.0005146 0.973
MDMB-CHMINACA 0.5 2–500 1/x Quadratic −0.1915 x2+3.181 x+0.3453 0.8686
MMB-2201 0.4 2–750 1/x2 Linear 0.8861 x+0.152 0.9845
PB-22 0.4 2–750 1/x Quadratic −0.03439 x2+1.358 x+0.1977 0.9927
RCS-4 0.5 2–750 1/x Linear 0.6175 x+0.0641 0.998
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Table 1 (continued)
Compound LOD (ng/g) Calibration
range (ng/g)
Weight Model Equation Squared correlation
coefficient (r2)
RCS-8 0.4 2–750 1/x Linear 0.334 x+0.0317 0.9999
STS-135 0.3 2–750 1/x2 Linear 0.3803 x+0.0396 0.9314
UR-144 0.3 2–750 1/x Linear 0.117 x+0.006706 0.9999
UR-144-5-OH 0.3 2–750 1/x2 Linear 0.415 x+0.05968 0.9903
WIN-48 0.2 10–750 1/x2 Linear 0.4263 x+0.04025 0.9742
WIN-55 0.2 10–750 1/x2 Linear 0.4956 x − 0.02026 0.9757
XLR-11 0.3 2–750 1/x2 Linear 0.2441 x+0.02587 0.9988
Synthetic cathinones and hallucinogens
25B-NBOMe 1 50–1000 1/x2 Quadratic −0.5271 x2+31.84 x+25.43 0.94
25C-NBOMe 0.7 2–750 1/x Quadratic −0.802 x2+26.85 x+5.498 0.9106
25H-NBOMe 0.3 2–750 1/x Quadratic −1.207 x2+42.43 x+13.83 0.9404
25I-NBOMe 2.3 2–1000 1 Quadratic −0.9354 x2+43.96 x+9.964 0.9641
2C-B 0.7 2–1000 1/x Quadratic −0.003879 x2+0.1796 x+0.03881 0.9913
2C-P 0.4 10–1000 1/x2 Quadratic −0.009927 x2+0.3245 x+0.09366 0.8786
3-4-DMMC 0.6 10–1000 1/x2 Linear 0.1401 x+0.006774 0.9837
4-Acetoxy-DiPT 0.1 10–1000 1/x2 Linear 0.1397 x+0.002963 0.9888
4-Acetoxy-DMT 0.2 10–1000 1/x2 Quadratic −0.01964 x2+0.7116 x+0.0764 0.9637
4-FA 0.8 2–750 1/x Linear 0.5245 x+0.1465 0.9968
4-F-Methcathinone 1.2 50–1000 1/x2 Linear 0.2239 x+−0.02987 0.9761
4-MEC 0.4 10–1000 1/x2 Quadratic −0.006333×2+0.1926 x+0.02581 0.9624
5-EAPB 0.1 10–1000 1/x2 Quadratic −0.1092 x2+4.679 x+0.1457 0.9896
5-MAPB 0.3 10–1000 1/x2 Linear 0.1197 x+0.00334 0.987
5-Methoxy AMT 0.7 10–1000 1/x2 Linear 0.09593 x+0.01237 0.9896
5-Methoxy DALT 0.9 2–1000 1/x Quadratic 0.01582 x2+0.7615 x+0.1362 0.9778
5-Methoxy DMT 0.2 2–750 1/x2 Linear 0.6774 x+0.1027 0.9972
5-Methoxy DiPT 0.6 2–750 1/x Linear 0.7815 x+0.05913 0.996
5-OH-tryptophan 1.2 2–750 1/x Quadratic −0.01051 x2+0.2862 x+0.05953 0.9695
6-APB 0.8 2–750 1/x Linear 0.4281 x+0.1081 0.9941
Buphedrone 2 50–1000 1/x2 Linear 1.026 x − 0.3712 0.977
Butylone 0.4 10–1000 1/x2 Quadratic −0.006513 x2+0.2355 x+0.02021 0.9905
DMT 0.3 2–750 1/x2 Linear 6.705 x+0.6186 0.9945
Ethylone 0.5 10–1000 1/x Quadratic −0.01085 x2+0.6566 x+0.1148 0.9955
Ethylphenidate 1.1 2–1000 1/x2 Quadratic −0.04227 x2+2.061 x+0.4308 0.9704
Ethyltryptamine 0.2 2–1000 1/x Quadratic −0.004067 x2+0.5112 x+0.01163 0.994
Harmine 1.3 2–1000 1/x Quadratic −0.007595 x2+0.3158 x+0.08406 0.9676
Ketamine 0.7 2–1000 1/x Linear 0.5291 x+0.1123 0.9987
LSD 0.5 2–1000 1/x Linear 0.464 x+0.05979 0.9962
mCPP 0.7 2–1000 1/x Linear 0.8268 x+0.1603 0.9993
MDPV 1.6 10–1000 1/x Linear 0.385 x+0.01433 0.9946
Mephedrone 0.6 50–1000 1/x2 Linear 0.3382 x+−0.05036 0.9907
Mescaline 0.3 10–1000 1/x2 Quadratic −0.007273 x2+0.2077 x+0.04462 0.9546
Methedrone 0.3 10–1000 1/x2 Linear 0.2777 x+0.0299 0.9877
Methylone 0.4 10–1000 1/x2 Quadratic −0.01108 x2+0.4579 x+0.03933 0.98
Mexedrone 2.3 50–1000 1/x2 Linear 0.03122 x+0.04465 0.9656
Mitragynine 0.1 10–1000 1/x2 Quadratic −0.002645 x2+0.2982 x+0.004006 0.9931
N-Ethylcathinone 2.4 50–1000 1/x2 Linear 0.01482 x − 0.004482 0.9662
N-Ethylpentylone 0.2 10–1000 1/x2 Quadratic −0.008614 x2+0.3912 x+0.02911 0.9862
PCP 1.6 2–750 1 Linear 0.6047 x+0.1403 0.9977
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Table 1 (continued)
Compound LOD (ng/g) Calibration
range (ng/g)
Weight Model Equation Squared correlation
coefficient (r2)
4-MeO-PCP 0.7 10–1000 1/x Linear 0.5299 x+0.09312 0.9983
Pentedrone 0.4 10–1000 1/x2 Linear 0.1635 x+0.004438 0.9824
Pentylone 0.2 10–1000 1/x Quadratic −0.004814 x2+0.3041 x+0.0185 0.9898
PMA 0.8 2–750 1/x Linear 0.3182 x+0.08759 0.9979
PMMA 0.9 2–750 1/x Linear 0.6716 x+0.201 0.9942
Psilocin 0.4 10–1000 1/x2 Linear 0.1752 x+0.00455 0.9967
Ritanilic acid 0.3 10–1000 1/x2 Linear 0.2817 x+0.05225 0.9991
Trazodone 0.9 2–1000 1/x Linear 0.5529 x+0.1541 0.9939
α-PVP 0.2 10–1000 1/x2 Linear 0.2971 x+0.01806 0.9929
Fentanyl analogs and synthetic opioids
3-Methylnorfentanyl 0.1 10–1000 1/x2 Quadratic −0.001644 x2+0.1505 x − 0.001454 0.9933
4-ANPP 0.7 2–1000 1/x Quadratic −0.002447 x2+0.1769 x+0.03207 0.9942
4-F-Butyrylfentanyl 0.1 10–750 1/x2 Linear 0.3749 x+0.007014 0.9971
4-Methyl fentanyl 0.1 10–750 1/x2 Quadratic −0.003541 x2+0.283 x+0.00173 0.9987
Acetyl fentanyl 0.1 10–1000 1/x2 Quadratic −0.02346 x2+0.7346 x+0.02761 0.9866
Acetyl norfentanyl 0.2 10–750 1/x2 Quadratic −0.00545 x2+0.2208 x+0.009908 0.9802
Acrylfentanyl 0.2 10–750 1/x2 Quadratic −0.02201 x2+0.6496 x+0.01222 0.951
AH-7921 0.2 10–1000 1/x2 Linear 0.1083 x − 0.0008527 0.9945
Alfentanyl 0.3 10–750 1/x2 Quadratic −0.02268 x2+0.4726 x+0.05711 0.838
Butyrylfentanyl 0.1 10–750 1/x2 Quadratic −0.01204 x2+0.5849 x − 0.004432 0.995
Butyryl fentanyl carboxy metabolite 0.7 2–750 1/x Linear 0.3062 x+0.06538 0.9955
Butyryl norfentanyl 0.5 2–750 1/x Quadratic −0.006895 x2+0.3085 x+0.04378 0.988
Carfentanyl 0.1 10–1000 1/x2 Quadratic −0.002613 x2+0.1908 x+0.00934 0.995
Cyclopropylfentanyl 0.1 10–750 1/x2 Quadratic −0.005917 x2+0.4781 x+0.003248 0.9983
Despropionyl p-fluorofentanyl 0.3 10–1000 1/x2 Linear 0.1468 x+0.0009262 0.9919
Fentanyl 2.2 10–1000 1 Quadratic −0.006104 x2+0.4574 x+0.08624 0.9923
Furanylfentanyl 0.2 10–750 1/x2 Quadratic −0.01427 x2+0.6959 x+0.01409 0.9918
Furanylnorfentanyl 0.2 10–750 1/x2 Quadratic −0.01182 x2+0.3486 x+0.007127 0.9784
Hydrocodone 0.5 10–1000 1/x2 Linear 0.02651 x+0.001894 0.9932
Methoxyacetyl norfentanyl 0.1 10–750 1/x2 Quadratic −0.004828 x2+0.1743 x+0.01007 0.9957
MT-45 0.3 10–750 1/x2 Linear 0.2524 x+0.03461 0.9803
Norfentanyl 0.5 50–1000 1/x2 Quadratic −0.009264 x2+0.4635 x+0.1825 0.9847
Ocfentanyl 0.1 10–1000 1/x2 Quadratic −0.01969 x2+0.776 x+0.0339 0.9816
OH-fentanyl 0.1 10–1000 1/x2 Quadratic −0.00299 x2+0.17 x+−8.721e−06 0.9912
Thiofentanyl 0.2 10–1000 1/x2 Quadratic −0.003418 x2+0.1964 x+0.0002254 0.994
Oxycodone 0.6 10–1000 1/x2 Linear 0.1192 x+0.01877 0.9919
Phenylacetyl fentanyl 0.5 2–1000 1/x Linear 0.3061 x+0.03762 0.9996
4-Phenylfentanyl 0.1 10–750 1/x2 Linear 0.5208 x+0.01129 0.9975
Remifentanyl 0.6 2–750 1/x2 Quadratic −0.009414 x2+0.2978 x+0.0546 0.9577
Sufentanyl 0.1 10–1000 1/x2 Quadratic −0.001314 x2+0.08714 x − 0.001218 0.9985
Tramadol 0.2 10–750 1/x2 Quadratic −0.03904 x2+1.088 x+0.0874 0.9322
U47700 0.3 10–750 1/x2 Quadratic −0.01362 x2+0.3489 x+0.02041 0.9039
Valeryl fentanyl carboxy metabolite 0.1 10–1000 1/x2 Quadratic −0.002608 x2+0.1907 x+0.009362 0.995
β-Phenylfentanyl 0.1 10–750 1/x2 Quadratic −0.008265 x2+0.3967 x − 0.002192 0.974
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Table 2 Inter-day precision, expressed in terms of CV. Acceptable results are expected in the range ± 30%. Values exceeding 30% are reported in bold
Compound Calibration level (CV %)
Inter-d
1 2 3 4 5 6
Synthetic cannabinoids
5-Chloro-AB-PINACA 15.7 28.5 0.5 14.4 2.1 0.2
5-Chloro-TH-J018 0.1 3.5 9.4 11.4 6.5 12
5-F-AB-PINACA 15.5 30.1 0.9 18.2 6.1 1.5
5-F-ADB 4.9 29.4 11.5 23.6 1.1 11.8
5-F-APINACA 0.5 0.1 0 10.2 40.8 57.7
5-F-APP PICA 10.6 30.5 14 33.5 3.7 2.5
5-F-APP PINACA 0.9 11.3 8.4 15.8 2.5 11.4
5-F-CUMYL PINACA 0.9 2.6 22.9 25.9 15.9 29.5
5-F NNEI 2′-naphthyl isomer 7.4 37 21 27 2.6 6.2
AB-CHMINACA 5.9 33 2.2 20.4 4.1 8.4
AB-FUBINACA 28.7 48.5 4.1 19.4 4.4 0.7
AB-PINACA 1.2 2.2 18.3 6.9 2.5 5.6
ADB-FUBINACA 32.4 38.8 8.4 8.5 10.5 3.6
ADBICA 28.4 22.3 23.5 34.6 5.2 2.3
ADB-PINACA 3.4 18.6 2.1 18.8 3.9 2.4
AKB-48 APINACA 15 34 15 11 15 –
AM-1220 0.1 0 0.4 2.6 6.6 4
AM-2201 25.6 36.2 6.4 19 1.9 0.4
AM-2233 0.8 2.9 3.5 0.2 0.6 4.6
AM-694 4.9 26.2 16.7 39.1 0.9 2.1
APP-FUBINACA 9.1 45.9 7 10.9 30.2 2.7
CUMYL-PeGACLONE 0.9 8 3.3 24.3 23.6 44
JWH-007 44.6 53.4 1.2 9.8 4 1.8
JWH-015 35.5 42.1 11.4 9.4 13 4.3
JWH-016 10.5 32.9 15.8 32.1 1.6 2.8
JWH-018 11.3 32.7 16 32.4 1.6 2.9
JWH-019 22.9 30.2 3 8 3.7 0.4
JWH-020 0.2 2.5 8.8 15.9 7 5
JWH-073 0.1 2.3 10.7 1.2 19.1 23
JWH-081 15 48.4 10.4 28.6 5.2 0.4
JWH-098 3.4 15.3 10.7 3.5 3.1 22.9
JWH-122 16.3 29.8 6.2 11.6 8.2 4.4
JWH-147 1.5 9 3.9 9.2 6.9 1.9
JWH-203 4.4 24 5.6 16 1.9 0.1
JWH-210 8.2 45 8.7 30.6 6.4 4.1
JWH-250 0.1 1.7 17.8 26.2 – –
JWH-251 2.9 19.6 16.7 19.6 8.4 11.2
JWH-302 3.9 20.9 1.3 21.2 3.4 0.6
JWH-307 3.5 15.5 10.7 3.5 3.3 22.9
JWH-398 0.3 4.4 8.8 11 3.6 5
MAB-CHMINACA 5.4 31.7 8.1 32.4 6.3 8
MAM-2201 7.7 37.1 15.7 7.3 10.5 27.3
MDMB-CHMICA 4.8 10.7 7.2 29 9.9 –
MDMB-CHMINACA 32.9 39.4 2.7 6.4 3.5 33.1
MMB-2201 0.8 1.6 19.3 18.5 10.1 25.4
PB-22 15.2 26.3 2.5 13.1 10.4 11
RCS-4 16.9 23.6 4.3 14 4.8 1.9
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Table 2 (continued)
Compound Calibration level (CV %)
Inter-d
1 2 3 4 5 6
RCS-8 32 37.4 0.4 5.7 0.6 0.2
STS-135 6.6 35.2 1.5 27.4 23.5 20.5
UR-144 19.5 24.7 0.6 6 0.8 0.7
UR-144-5-OH 0.7 10.7 26.7 23.8 15.5 25
WIN-48 0.1 0.4 4.3 2 14.8 13
WIN-55 0.9 1 14 7.2 11.6 16.5
XLR-11 5.5 31.3 7 2.5 2.3 2.3
Synthetic cathinones and hallucinogens
25B-NBOMe 2.1 8.1 14.5 8 14.6 14
25C-NBOMe 8.2 19.1 11.6 1.6 4.5 30.2
25H-NBOMe 22.8 22.4 6.4 12.7 11.2 15.6
25I-NBOMe 20.9 12.5 0.1 9.6 15.8 7.5
2C-B 18.8 28.7 8.3 2.9 5.2 14.6
2C-P 2.6 17.9 1.6 25.4 10 –
3-4-DMMC 1.1 16.1 21.1 4.4 2.7 13.4
4-Acetoxy-DiPT 0.2 1.1 1.3 3.3 7.1 8.4
4-Acetoxy-DMT 1 7.5 4.8 5.1 13.9 –
4-FA 10.8 23.6 23.1 12.9 3.6 5.3
4-F-Methcathinone 2.1 10.1 17.7 5.1 17.4 2.8
4-MEC 0.5 0.1 8 23.2 22.8 –
5-EAPB 1.6 8.7 2.5 29.6 10.1 –
5-MAPB 0.6 4.5 3.4 7.6 2.9 10.8
5-Methoxy AMT 0.5 13.1 23.4 16.1 6 0.7
5-Methoxy DALT 8.2 11.5 2.1 1.5 1.5 3.6
5-Methoxy DMT 3.5 13.7 17.9 11.9 21 18.9
5-Methoxy DiPT 2.4 25.1 16.4 6.3 5.3 5.1
5-OH-tryptophan 20.2 9.3 14.2 0.3 13.1 –
6-APB 1.3 41.8 25.9 19.2 4.8 6.9
Buphedrone 5.3 14.9 15 9.6 6.3 10.6
Butylone 1.1 5.7 2.7 18.8 21.8 –
DMT 5.6 33.4 12.9 28.7 2.5 11.3
Ethylone 22.2 11.7 17.2 7.6 4.7 7.8
Ethylphenidate 5.3 4 3.5 7.3 7.5 4.6
Ethyltryptamine 4.8 11 5 13.5 6 3.5
Harmine 9.2 8.7 2.9 1.3 7.5 –
Ketamine 50.3 48.8 4.3 0.3 5.1 1.9
LSD 0.1 13.5 6.1 7.1 5.2 4.8
mCPP 28.6 55.9 9.9 20.6 2.7 0.7
MDPV 0 0.7 1.5 0.3 5 6
Mephedrone 1.5 4.8 4 6.4 9.6 2.5
Mescaline 1.8 12.7 5 21.9 38.2 –
Methedrone 2.5 9.9 6.8 0.2 0.3 14.3
Methylone 0.1 1.6 5.8 11.6 0.1 –
Mexedrone 2.2 12.8 30.8 13.3 13.9 7.1
Mitragynine 0.8 7.8 8.3 0.3 4.6 3.1
N-Ethylcathinone 11.2 15.6 32.3 17.8 20.3 1.5
N-Ethylpentylone 0.6 3.3 0.1 7.6 2.6 –
PCP 34.6 49.8 3.8 14.4 5.1 2
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Table 2 (continued)
Compound Calibration level (CV %)
Inter-d
1 2 3 4 5 6
4-MeO-PCP 27.1 15 15.3 4 2.9 2.2
Pentedrone 0 4.2 8.8 1.6 8.3 11.3
Pentylone 0.2 1.3 0.5 5.6 4.3 0.4
PMA 4.4 31.7 19.5 9 3.1 4.2
PMMA 12.1 33.6 29.9 17.8 4.7 7
Psilocin 0.4 2.6 1.9 7.7 5.7 2.1
Ritanilic acid 0.5 0.8 7.4 1.8 4.8 3
Trazodone 34.2 14.8 19.5 3 3.9 7.1
α-PVP 0.6 4.8 3.9 2.1 5 7.3
Fentanyl analogs and synthetic opioids
3-Methylnorfentanyl 0.1 1.7 4.5 8.4 6.7 0.6
4-ANPP 14.1 4.6 9.9 10.3 0.4 2.2
4-F-Butyrylfentanyl 0.5 1 3.8 1.9 7.1 0.9
4-Methyl fentanyl 0.1 2.6 5.7 2 4.7 3.9
Acetyl fentanyl 0 2.1 6.4 2.6 13.6 –
Acetyl norfentanyl 0.6 5 2.7 6 7.1 4.1
Acrylfentanyl 0.1 0.7 1.3 7.7 15.2 –
AH-7921 0.7 2.4 3.9 3.4 4.6 6.5
Alfentanyl 0.5 3.4 0.5 2.6 38.5 45.1
Butyrylfentanyl 0.7 5.2 2.8 0.6 7.5 9
Butyryl fentanyl carboxy metabolite 47.1 15.9 30.7 11.1 6.1 4.7
Butyryl norfentanyl 5.7 0.9 8.3 4.1 11.6 8.4
Carfentanyl 0.1 2.2 5.1 7.7 3.3 2.2
Cyclopropylfentanyl 0.3 4.1 6.9 1.1 5.9 4.3
Despropionyl p-fluorofentanyl 0.8 8.5 28.2 5.3 0.8 12.7
Fentanyl 71.5 18.2 2.5 1.4 1.8 0.6
Furanylfentanyl 0.1 0 0.6 3.9 11.8 10.6
Furanylnorfentanyl 0.5 1.3 5.5 4.9 19.9 –
Hydrocodone 4 29.4 17.2 3.2 11.4 0.1
Methoxyacetyl norfentanyl 1.5 6.2 11.4 21.8 10.9 –
MT-45 1.6 0.5 11.9 20.1 15.6 15.2
Norfentanyl 1.6 3.2 4.7 13.5 2.6 18.2
Ocfentanyl 0.4 0.8 4.6 57.7 11.4 –
OH-fentanyl 0.1 2.8 6.6 10.3 4.2 5.5
Thiofentanyl 0.5 1.2 3.6 12.1 3.5 9.1
Oxycodone 5.8 33.8 4.5 15.9 8.5 1.1
Phenylacetyl fentanyl 45.3 51.2 0.3 4.9 2.5 1.3
4-Phenylfentanyl 1.1 2.8 6.3 4.3 8.6 3.7
Remifentanyl 25.5 55.9 3.1 8.1 2.2 0.5
Sufentanyl 0.7 4.1 0 6.8 5.1 12
Tramadol 0.3 1.8 0.8 8.4 14.2 –
U47700 0.4 2.2 2.1 14.9 24.9 –
Valeryl fentanyl carboxy metabolite 0 2.2 5.1 7.7 3.3 2.1
β-Phenylfentanyl 0.9 1.5 1.9 5.5 24.9 31.9
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Table 3 Matrix effect at low (50 ng/g) and high (1000 ng/g)
concentration levels
Compound Matrix effect (n=5)
(±%)
50 ng/g 1000 ng/g
Synthetic cannabinoids
5-Chloro-AB-PINACA − 45 − 46
5-Chloro-TH-J018 − 21 16
5-F-AB-PINACA − 38 − 40
5-F-ADB − 23 − 22
5-F-APINACA − 43 − 47
5-F-APP PICA − 32 − 39
5-F-APP PINACA − 40 − 51
5-F-CUMYL PINACA − 70 − 33
5-F NNEI 2′-naphthyl isomer − 70 − 35
AB-CHMINACA − 36 − 27
AB-FUBINACA − 49 2
AB-PINACA − 32 − 43
ADB-FUBINACA − 37 − 40
ADBICA − 26 − 30
ADB-PINACA − 17 − 28
AKB-48 APINACA − 49 − 25
AM-1220 − 16 − 22
AM-2201 − 46 − 45
AM-2233 − 48 − 40
AM-694 − 26 − 24
APP-FUBINACA − 60 − 54
CUMYL-PeGACLONE 33 72
JWH-007 − 33 − 40
JWH-015 − 31 − 30
JWH-016 24 29
JWH-018 − 18 − 12
JWH-019 − 39 − 13
JWH-020 − 45 − 18
JWH-073 − 14 − 17
JWH-081 − 6 − 5
JWH-098 − 26 8
JWH-122 − 39 − 13
JWH-147 − 42 − 36
JWH-203 − 38 − 22
JWH-210 − 49 − 46
JWH-250 − 27 − 23
JWH-251 − 6 − 12
JWH-302 − 39 − 18
JWH-307 − 26 − 30
JWH-398 − 50 − 40
MAB-CHMINACA − 19 − 15
MAM-2201 − 10 4
MDMB-CHMICA − 26 − 23
MDMB-CHMINACA − 43 − 33
Table 3 (continued)
Compound Matrix effect (n = 5)
(±%)
50 ng/g 1000 ng/g
MMB-2201 17 20
PB-22 − 16 − 18
RCS-4 − 20 13
RCS-8 − 27 7
STS-135 − 60 − 23
UR-144 − 44 − 8
UR-144-5-OH − 28 17
WIN-48 − 50 − 50
WIN-55 − 43 − 45
XLR-11 − 37 − 36
Synthetic cathinones and hallucinogens
25B-NBOMe − 81 − 50
25C-NBOMe − 80 − 55
25H-NBOMe − 75 − 41
25I-NBOMe − 80 − 52
2C-B 28 50
2C-P 48 46
3-4-DMMC − 78 − 72
4-Acetoxy-DiPT − 66 − 89
4-Acetoxy-DMT − 74 − 70
4-FA − 20 − 21
4-F-Methcathinone 1 − 3
4-MEC − 52 − 50
5-EAPB − 77 − 60
5-MAPB − 76 − 63
5-Methoxy AMT − 78 − 80
5-Methoxy DALT − 77 − 73
5-Methoxy DMT − 78 − 71
5-Methoxy DiPT − 78 − 71
5-OH-Tryptophan − 61 − 51
6-APB − 75 − 74
Buphedrone − 13 − 5
Butylone − 31 − 13
DMT 13 45
Ethylone 31 71
Ethylphenidate − 68 − 50
Ethyltryptamine − 72 − 70
Harmine − 71 − 71
Ketamine 6 8
LSD − 75 − 62
mCPP − 77 − 71
MDPV − 65 − 52
Mephedrone − 67 − 65
Mescaline 46 70
Methedrone − 39 − 34
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Application to real specimens
Fentanyl, likemany other drugs, can cross the placental barrier
and thus reach the fetus, even when administered in epidural
anesthesia [27]. Moreover, identification of several drugs has
been reported in meconium after intake during labor [28–30].
Therefore, 30 meconium specimens from newborns whose
mothers were administered this drug through epidural anes-
thesia were analyzed to verify the possibility to detect fentanyl
and/or its main metabolites. These specimens were from cases
in which fentanyl had been administered as epidural anesthe-
sia at the time of delivery (n = 27) or cases in which the ma-
ternal hair was positive to other drug of abuse (n = 3) tested
after delivery.
Four meconium specimens tested positive for fentanyl
(range 440–750 ng/g) and two specimens tested positive to
acetylfentanyl (range 190–1400 ng/g). Three of the fentanyl-
positive meconium samples (case 10, 13, and 26; at the con-
centration of 520 ng/g, 450 ng/g, and 750 ng/g, respectively)
were cases in which fentanyl was administered as epidural
anesthesia. Moreover, in case 13, the maternal hair also tested
positive for fentanyl (5.0, 5.7, and 4.9 pg/mg for the first,
second, and third trimesters, respectively) by using a validated
method [22]. But the concentrations in hair were very low and
fentanyl was also detected in the last wash, probably due to a
contamination during labor. Finally, in the fourth case which
tested positive (case 30; at the concentration of 440 ng/g),
fentanyl was not administered as epidural anesthesia or detect-
ed in maternal hair, an unauthorized intake of fentanyl has
likely occurred. Furthermore, the maternal hair tested positive
for MDMA in the first trimester of pregnancy (162.2 pg/mg).
Quite remarkably, norfentanyl was never detected in meconi-
um, albeit the relatively high concentrations of fentanyl and
the low LOD for norfentanyl (0.5 ng/g). This finding suggests
that fentanyl is poorly metabolized or barely adsorbed by
newborns, opening two different scenarios about the effects
of fentanyl administrations to infants which would deserve
further evaluations.
Table 3 (continued)
Compound Matrix effect (n = 5)
(±%)
50 ng/g 1000 ng/g
Methylone − 40 − 42




PCP − 4 3
4-MeO-PCP − 14 − 4
Pentedrone − 3 6
Pentylone 28 30
PMA − 16 1
PMMA 27 8
Psilocin 32 32
Ritanilic acid 9 34
Trazodone 9 30
α-PVP 2 9
Fentanyl analogous and synthetic opioids
3-Methylnorfentanyl − 11 − 12
4-ANPP − 76 − 71
4-F-Butyrylfentanyl − 78 − 68
4-Methyl fentanyl − 78 − 75
Acetyl fentanyl − 70 − 57
Acetyl norfentanyl − 4 − 9




Butyryl fentanyl carboxy metabolite 19 2
Butyryl norfentanyl − 72 − 54
Carfentanyl 1 − 3
Cyclopropylfentanyl − 1 10
Despropionyl p-fluorofentanyl 28 33
Fentanyl 27 38
Furanylfentanyl 78 110
Furanylnorfentanyl − 1 11
Hydrocodone 16 − 14
Methoxyacetyl norfentanyl 25 48
MT-45 − 84 − 74
Norfentanyl − 50 − 16
Ocfentanyl 8 34
OH-Fentanyl − 77 − 78
Thiofentanyl − 76 − 76
Oxycodone − 11 − 5
Phenylacetyl fentanyl − 73 − 72
4-Phenylfentanyl − 76 − 66
Remifentanyl 11 74
Table 3 (continued)
Compound Matrix effect (n = 5)
(±%)
50 ng/g 1000 ng/g
Sufentanyl − 47 − 9
Tramadol − 60 − 57
U47700 − 74 − 63
Valeryl fentanyl carboxy metabolite − 78 − 70
β-Phenylfentanyl − 77 − 88
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Figure 1 shows the chromatogram from a real positive
sample. Table 4 shows the positive meconium specimens
along with the information about the epidural anesthesia re-
ceived by the mother and results in maternal hair.
Conclusions
A method that allows the simultaneous determination of 137
new psychoactive substances (including synthetic cathinones,
hallucinogens, synthetic cannabinoids, fentanyl analogs, and
other synthetic opioids) in meconium was developed and val-
idated for semi-quantitative purpose. This was the first attempt
to use new technologies such as QTOF mass spectrometry for
a broad-spectrum drug screening in meconium. In terms of
analytical performances, the method proved fit for its purpose.
In particular, the very low LODs seem adequate to detect the
presence of NPS after the ingestion of active doses from the
mother. Unfortunately, the limited number of real samples,
and especially the lack of real samples positive to targeted
compounds other than fentanyl, prevent us to confirm the
former statement. A further limitation of this analytical meth-
od is the cumbersome sample preparation prior the analysis
(homogenization and SPE). However, meconium is a very
complex biological matrix, so its analysis using simpler pro-
cesses such as “dilute and shoot” is not possible. On the other
hand, HRMS screening methods can become of particular
interest in the modern drug market dominated by NPS. In fact,
the UHPLC-QTOF equipment provides high mass accuracy
and accurate isotopic patterns which in turn allows confidence
for the identification of NPS. Furthermore, newly discovered
NPS can be added to the panel of target analytes to look for the
presence of these new substance without adjusting the extrac-
tion method, which is very promising with the continuously
Table 4 Positive meconium
specimens (semiquantitative
results), information about the
epidural anesthesia, and results in
maternal hair











Yes 1° trim: 5.0
2° trim: 5.7
3° trim: 4.9
26 Fentanyl 750 Yes
30 Fentanyl 440 No
Empty boxes represent negative results
Trim trimester
Fig. 1 Chromatogram from a real sample positive to fentanyl and acetylfentanyl
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changing drugmarket of NPS. In the future, only the routinary
application of drug screening in meconiumwill allow to better
understand the actual prevalence of NPS consumption among
pregnant women.
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